10am EST (NA) / 3pm GMT (UK) / 4pm CET (EU-Central)

In this informative webinar, discover strategies for patient engagement and digital therapeutics relating to the management of social determinants of health in cardiometabolic diseases and recent Food and Drug Administration (FDA) guidance on the future of Lupus research.

The impact of a therapeutic intervention on health outcomes isn’t caused by the efficacy demonstrated in pivotal confirmatory studies, but by the effectiveness the intervention demonstrates in the real world when used by patients. A major cause for the gap between efficacy in confirmatory studies and the real world is due to social determinants of health, which according to the World Health Organization (WHO), American Disability Association (ADA) and others account for 30-55% of the impact on health outcomes.

Characterizing social determinants of health in development programs by means of validated psychometric and behavioral instruments is critical to begin deriving digital therapeutics to mitigate this gap effectively.

When engaging in patient-focused drug development, it’s imperative to have a holistic approach to individuals, their predispositions and their life choices to embrace the whole human that ultimately will benefit from the innovation. This can only happen when insights are captured through a seamless site and patient experience solution.

Join this webinar to explore the importance of social determinants of health in achieving optimal health outcomes for cardiometabolic diseases, such as obesity, type 2 diabetes and ischemic heart disease. The featured speakers will discuss the promise of digital therapeutics to augment drug therapeutic interventions. The experts will also discuss recent FDA guidance and share their vision of the future of Lupus research and opportunities to drive Lupus research forward.